
Diabetes doubles risk for heart failure
Recent clinical trials of new glucose-lowering treatments have drawn attention to the importance of hospitalization for heart failure as a...

XyloCor Therapeutics bags US$17m in Series A financing
The Amsterdam-based company said it will primarily use the proceeds to advance its lead product XC001, licenced from Weill Cornell Medicine, to...

EC advisors call for update of GM legislation
The seven advisiors of the EU Commission (SAM) call on the European Commission (EC) to revise the existing GMO directive 2001/18/EC because the...

Valneva inks $59m JE vaccine supply contract
Under the agreement, Valneva will supply its FDA-approved preventive vaccine for Japanese encephalitis (JE) from 2019 to 2020. There is a minimum...

SOBI and AstraZeneca in US$2bn+ deal on RSV antibodies
Though Synagis biosimilars are under development at South Korean Celltrion, Mabxience and Chinese iBio, palivizumab is currently the only...

Tissue specific tumour transition needs few cells
Anja Voss-Böhme from University Dresden and researchers at the German Cancer Center in Heidelberg used a model that links epigenetic and genetic...

New cheap CRS-blockers at the horizon
In mice, the team headed by Bert Vogelstein and Shibin Zhou from Johns-Hopkins University in Baltimore demonstrated that severe...